Intravenous iron-gluconate during haemodialysis modifies plasma β2-microglobulin properties and levels

Nephrology Dialysis Transplantation

Volumn 20, Issue 9, 2005, Pages 1963-1969

  Michelis, Regina ^a   Sela, Shifra ^a,b   Kristal, Batya ^a,b  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Advanced glycation end products; Carbonyl; Iron gluconate; Low flux; Protein oxidation

Indexed keywords

2,4 DINITROPHENYLHYDRAZINE; BETA 2 MICROGLOBULIN; CELLULOSE TRIACETATE; FERRIC GLUCONATE; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS MEMBRANE; DOSE RESPONSE; DRUG INFUSION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IN VIVO STUDY; ISOELECTRIC POINT; KIDNEY FAILURE; MALE; MOLECULAR WEIGHT; OXIDATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MODIFICATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BETA 2-MICROGLOBULIN; DIABETES COMPLICATIONS; FEMALE; FERRIC COMPOUNDS; GLUCONATES; HUMANS; INFUSIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; RENAL DIALYSIS;

EID: 24044536322     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh907     Document Type: Article

References (23)

1. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: S182-S238
2. ERA/EDTA. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 [Suppl 15]: 1-50
3. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma non-transferrin bound iron (NTBI) in dialysis patients. Eur J Clin Inv 2002; 32 [Suppl 1]: 42-49
4. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000; 15: 1827-1834
5. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-2687
6. Michelis R, Gery R, Sela S et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003; 18: 924-930
7. Anraku M, Kitamura K, Shinohara A et al. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 2004; 66: 841-848
8. Cary NR, Sethi D, Brown EA, Erhardt CC, Woodrow DF, Gower PE. Dialysis arthropathy: Amyloid or iron? Br Med J 1986; 293: 1392-1394
9. Hurst NP, van den Berg R, Disney A et al. 'Dialysis related arthropathy': A survey of 95 patients receiving chronic haemodialysis with special reference to beta 2 microglobulin related amyloidosis. Ann Rheum Dis 1989; 48: 409-420
10. Hörl WH. Hemodialysis membranes: Interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002; 13 [Suppl 1]: S62-S71
11. Drueke TB. Beta2-microglobulin and amyloidosis. Nephrol Dial Transplant 2000; 15 [Suppl 1]: 17-24
12. Miyata T, Oda O, Inagi R et al. β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243-1452
13. DiRaimondo CR, Pollak VE. Beta 2-microglobulin kinetics in maintenance hemodialysis: A comparison of conventional and high-flux dialyzers and the effects of dialyzer reuse. Am J Kidney Dis 1989; 13: 390-395
14. 2-microglobulin removal during haemodialysis, haemodiafiltration and haemofiltration. Nephrol Dial Transplant 1989; 4: 653-657
15. Locatelli F, Andrulli S, Pecchini F et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1399-1409
16. Zingraff J, Beyne P, Urena P et al. Influence of haemodialysis membranes on beta 2-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988; 3: 284-290
17. Moachon N, Boullange C, Fraud S, Vial E, Thomas M, Quash G. Influence of the charge of low molecular weight proteins on their efficacy of filtration and/or adsorption on dialysis membranes with different intrinsic properties. Biomaterials 2002; 23: 651-658
18. Clark WR, Macias WL, Molitoris BA, Wang NH. Plasma protein adsorption to highly permeable hemodialysis membranes. Kidney Int 1995; 48: 481-488
19. Randoux C, Gillery P, Georges N, Lavaud S, Chanard J. Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes. Kidney Int 2001; 60: 1571-1577
20. Sethi D, Gower PE. Dialysis arthropathy, beta 2-microglobulin and the effect of dialyser membrane. Nephrol Dial Transplant 1988; 3: 768-772
21. Connors LH, Shirahama T, Skinner M, Fenves A, Cohen AS. In vitro formation of amyloid fibrils from intact beta 2-microglobulin. Biochem Biophys Res Commun 1985; 131: 1063-1068
22. Harrison PM, Arosio P. The ferritins: Molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161-203
23. Kirschbaum B. Hypotransferrinemia of chronically hemodialyzed patients. Artif Organs 1999; 23: 1047-1054